Eribulin Suppresses New Metastases in Patients With Metastatic Breast Cancer

In Vivo - Greece
doi 10.21873/invivo.11858
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Anticancer Research USA Inc.

Related search

Brain Metastases in Patients With Metastatic Breast Cancer : Prognosis According to Subtype

Nihon Rinsho Geka Gakkai Zasshi (Journal of Japan Surgical Association)
2017English

Eribulin Mesylate in the Treatment of Metastatic Breast Cancer

Biologics: Targets and Therapy
OncologyImmunologyGastroenterologyPharmacologyRheumatologyAllergy
2012English

Analysis of Eribulin Mesylate Dosing Modifications Impact on Administration Persistence in Patients With Metastatic Breast Cancer (Mbc)

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2015English

Eribulin in Pretreated Metastatic Breast Cancer Patients: Results of the TROTTER Trial—a Multicenter Retrospective Study of Eribulin in Real Life

SpringerPlus
Multidisciplinary
2016English

Use of Eribulin as an Earlier-Line Chemotherapy for Patients With HER2-negative Metastatic Breast Cancer

Journal of Cancer
Oncology
2020English

Outcome of Eribulin as a Late Treatment Line for Thai Metastatic Breast Cancer Patients

OncoTargets and Therapy
OncologyPharmacology
2018English

Oral Fluoropyrimidines Among the New Drugs for Patients With Metastatic Breast Cancer

British Journal of Cancer
Cancer ResearchOncology
2001English

Management of Patients With Metastatic Renal Cell Cancer and Bone Metastases

In Vivo
BiochemistryMedicineGeneticsPharmacologyMolecular Biology
2020English

Disease-Free Survival in Patients With Non-Metastatic Breast Cancer

Revista da Associacao Medica Brasileira
Medicine
2016English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy